Oncozenge AB Total Liabilities
Oncozenge AB total liabilities. Based on the latest financial reports, Oncozenge AB (ONCOZ) has total liabilities worth Skr15.92 Million SEK (≈ $1.71 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Oncozenge AB liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Oncozenge AB (2020–2025)
Total liabilities of Oncozenge AB from 2020 to 2025. This chart illustrates how Oncozenge AB's total liabilities have evolved over time, based on quarterly financial data.
Oncozenge AB Competitors by Total Liabilities
The table below lists competitors of Oncozenge AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pantera Lithium Ltd
AU:PFE
|
Australia | AU$8.20 Million |
|
ArcWest Exploration Inc
V:AWX
|
Canada | CA$989.09K |
|
CF Energy Corp
V:CFY
|
Canada | CA$849.83 Million |
|
Marston’s PLC
LSE:MARS
|
UK | GBX1.53 Billion |
|
Noronex Ltd
AU:NRX
|
Australia | AU$1.04 Million |
|
Bhuwanatala Indah Permai Tbk
JK:BIPP
|
Indonesia | Rp847.08 Billion |
|
Xpon Technologies Group Ltd
AU:XPN
|
Australia | AU$16.05 Million |
|
One SA
WAR:FMG
|
Poland | zł47.35 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Oncozenge AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ONCOZ asset base.
Liquidity & Leverage Metrics
Oncozenge AB Total Liabilities Ratios Explained
Oncozenge AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -27.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncozenge AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncozenge AB (2020–2025)
The table below shows the annual total liabilities of Oncozenge AB from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr15.92 Million ≈ $1.71 Million |
+973.05% |
| 2024-12-31 | Skr1.48 Million ≈ $159.70K |
-12.65% |
| 2023-12-31 | Skr1.70 Million ≈ $182.84K |
-41.82% |
| 2022-12-31 | Skr2.92 Million ≈ $314.24K |
-40.46% |
| 2021-12-31 | Skr4.90 Million ≈ $527.75K |
-45.60% |
| 2020-12-31 | Skr9.01 Million ≈ $970.05K |
-- |
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.